Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center, Double-Blind, Placebo-Controlled, Dose-Escalating Phase Ia Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Characteristics of EA5 in a Single Dose in Adult Healthy Subjects

NCT07256288 is registered in ClinicalTrials.gov with Shanghai Lanyi Therapeutics Co., Ltd. as lead sponsor.

NCT NCT07256288
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07256288 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center, Double-Blind, Placebo-Controlled, Dose-Escalating Phase Ia Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Characteristics of EA5 in a Single Dose in Adult Healthy Subjects
Lead sponsor
Shanghai Lanyi Therapeutics Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2023
Completion date
August 1, 2024
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers